By AJ Fabino, Senior Editor, Stock Trader Network

Robinhood (HOOD) is preparing to put a portfolio of startups most investors have never heard of on the New York Stock Exchange, offering the public exposure to its venture-capital fund.

Robinhood Ventures Fund II, or RVII, expects to sell as many as 8 million shares at $25 apiece and begin trading August 13 under the ticker RVII. The fund will issue up to 7.6 million shares, while Robinhood Markets will sell another 400,000 and keep those proceeds.

Requests for IPO shares are expected to close Aug. 12.

RVII is a business development company built principally around current and former Y Combinator startups. Its portfolio page listed 81 holdings, nearly two-thirds in tech. Readers can view the fund’s complete holdings on Robinhood’s RVII portfolio page.

Stock Trader Network researched each holding and screened out businesses with too little public evidence. Five stood apart through commercial traction, technical difficulty and exposure to markets nearing an inflection point.

Five RVII startups to watch

• Tasklet: AI agents that keep working across workplace software after employees log off.
• Didit: One API for identity verification, fraud monitoring and crypto-wallet screening.
• Luel: Rights-cleared training data for robotics, speech and generative-AI systems.
• CellType: Biological foundation models that simulate how human cells and tissues respond to drugs.
• Adialante: A compact mobile MRI system offered to clinics through a per-scan model.

Why these five made the list

Tasklet

Tasklet may be the bet with the highest ceiling, as its cloud-based AI agents connect with workplace software and continue handling tasks after employees close their laptops. 

It reported in April that it had $5 million in annual recurring revenue, growth of more than 1,200% since January 1 and a $20 million financing at a $175 million valuation. Co-founder Andrew Lee built Firebase, which Google (GOOG) acquired; Jonny Dimond helped develop it and later led Google Cloud Firestore technically. Tasklet will face Microsoft (MSFT), Salesforce (CRM), ServiceNow (NOW) and nearly every major AI lab. Still, it has the strongest mix of founders, revenue and a route to becoming the operating layer for autonomous work.

Didit

Didit is attacking a problem that becomes more valuable with every convincing deepfake. The company says it is profitable, growing more than 30% a month and serving over 2,000 businesses. Spanish financial authorities have tested its tech through the country’s regulatory sandbox, according to Cinco Días. Websites increasingly need to determine whether a person, payment or AI agent is genuine. Didit could become a developer-friendly identity utility, provided it outruns established rivals and manages the business’s security risks.

Luel

Luel supplies a scarce commodity—human-generated training data that AI companies can legally use. Lightspeed Venture Partners, which led a $31.2 million financing, says Luel can reach more than 500,000 contributors across 96 countries. Completed datasets can be licensed repeatedly, offering better economics than one-off data labeling. Meta’s $14.3 billion investment in Scale AI showed the strategic value of such suppliers. Luel must preserve quality, consent and contributor trust at scale.

CellType

CellType carries the portfolio’s largest scientific upside. The Yale spinout’s Cell2Sentence research was published at the International Conference on Machine Learning, and the company says it predicted and validated a previously unknown cancer-treatment signal in the laboratory. It also reports inbound work with an unnamed top-10 pharmaceutical company. The distance between a laboratory result and an approved medicine is vast, making this one of RVII’s most consequential and binary wagers.

Adialante

Adialante offers a nearer-term test. It assembled its mobile MRI scanner for less than $1 million and says 11 clinics have signed letters of intent worth nearly $20 million, according to Twin Cities Business. FDA clearance is the gate, as approval and reliable deployments could turn MRI from a hospital capital expense into a recurring service. If clearance slips, the letters will remain just that.